-
December 2, 2019
Clinical Impact of New Data in B-Cell Malignancies From 2019 EHA and ICMLBookmark
George Lundberg, MDContinuing medical education course from Clinical Care Options curated by Editor in Chief George Lundberg, MD, who notes:
Recent research findings can change practices for B-cell malignancies.
Go to educational module at Clinical Care Options (requires free registration).
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Pembrolizumab Plus Lenvatinib Approved for Endometrial CancerBookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved a new combination therapy for certain advanced endometrial cancers.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial CarcinomaBookmark
George Lundberg, MDPress release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
The FDA has granted accelerated approval for the drug erlofitinib in advanced urothelial malignancies that meet specific criteria.
Go to full article published by the FDA.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney CancersBookmark
George Lundberg, MDArticle from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes:
In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.
Go to full article published by Targeted Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Ovarian Cancer: Is This the Beginning of the End?Bookmark
George Lundberg, MDArticle from Healio curated by Editor in Chief George Lundberg, MD, who notes:
This piece discusses recent insights into ovarian cancer, including the fact that this type of cancer sometimes originates in the fallopian tube, and that drugs known as PARP inhibitors show great therapeutic promise.
Go to full article published by Healio.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
FDA Approves Acalabrutinib for CLL/SLL as Part of Project OrbisBookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.
Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
FDA Approves Therapy to Treat Patients with Relapsed and Refractory Mantle Cell Lymphoma Supported by Clinical Trial Results Showing High Response Rate of Tumor ShrinkageBookmark
George Lundberg, MDPress release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
Of the non-Hodgkin lymphomas, mantle cell lymphoma can be especially difficult to treat. The FDA has now announced accelerated approval for the drug zanubrutinib (Brukinsa) after it showed strong effects for patient in single-arm clinical trials.
Go to full article published by the U.S. Food and Drug Administration (FDA).
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Biological Activity of Weekly ONC201 in Adult Recurrent Glioblastoma PatientsBookmark
George Lundberg, MDResearch paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes:
This paper reports the results of an investigation of the drug ONC201 in adults with recurrent glioblastoma (GBM). It found that ONC201 penetrated the blood-brain barrier and achieved intratumoral levels without toxicity. While most GBMs were not responsive, one patient with the mutation H3 K27M experienced a prolonged remission.
Go to full paper published in Neuro-Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
November 12, 2019
Novel Agents Influence the Development of New Strategies for Treatment of Bladder CancerBookmark
George Lundberg, MDArticle from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Once bladder cancer has infiltrated the muscle wall in elderly patients, it becomes challenging to treat. New drugs and immunotherapies show some promise.
Go to full article published by Targeted Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
November 12, 2019
Microwave Ablation Feasible for cT1b Renal Cell CarcinomaBookmark
George Lundberg, MDArticle from Renal and Urology News curated by Editor in Chief George Lundberg, MD, who notes:
Microwave ablation has been shown to be a viable alternative to both radical and partial nephrectomy for kidney cancers that measure less than 7 cm in diameter. Outcomes for the two approaches are comparable.
Go to full article published by Renal and Urology News.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Treatment Options
Learn about the latest treatments for advanced cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.
